Epigral Ltd. (EPIGRAL) - Net Assets
Based on the latest financial reports, Epigral Ltd. (EPIGRAL) has net assets worth Rs22.21 Billion INR (≈ $240.24 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs35.05 Billion ≈ $379.08 Million USD) and total liabilities (Rs12.84 Billion ≈ $138.85 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Epigral Ltd.'s equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs22.21 Billion |
| % of Total Assets | 63.37% |
| Annual Growth Rate | 23.38% |
| 5-Year Change | 205.99% |
| 10-Year Change | 514.13% |
| Growth Volatility | 16.79 |
Epigral Ltd. - Net Assets Trend (2015–2026)
This chart illustrates how Epigral Ltd.'s net assets have evolved over time, based on quarterly financial data. See EPIGRAL cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Epigral Ltd. (2015–2026)
The table below shows the annual net assets of Epigral Ltd. from 2015 to 2026. For live valuation and market cap data, see EPIGRAL company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | Rs22.21 Billion ≈ $240.24 Million |
+16.64% |
| 2025-03-31 | Rs19.05 Billion ≈ $205.97 Million |
+51.86% |
| 2024-03-31 | Rs12.54 Billion ≈ $135.63 Million |
+17.30% |
| 2023-03-31 | Rs10.69 Billion ≈ $115.62 Million |
+47.27% |
| 2022-03-31 | Rs7.26 Billion ≈ $78.51 Million |
+6.12% |
| 2021-03-31 | Rs6.84 Billion ≈ $73.99 Million |
+17.25% |
| 2020-03-31 | Rs5.83 Billion ≈ $63.10 Million |
+18.41% |
| 2019-03-31 | Rs4.93 Billion ≈ $53.29 Million |
-4.75% |
| 2018-03-31 | Rs5.17 Billion ≈ $55.95 Million |
+43.02% |
| 2017-03-31 | Rs3.62 Billion ≈ $39.12 Million |
+22.56% |
| 2016-03-31 | Rs2.95 Billion ≈ $31.92 Million |
+34.01% |
| 2015-03-31 | Rs2.20 Billion ≈ $23.82 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Epigral Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 25988.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2026)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs21.02 Billion | 94.62% |
| Common Stock | Rs431.40 Million | 1.94% |
| Other Components | Rs764.50 Million | 3.44% |
| Total Equity | Rs22.21 Billion | 100.00% |
Epigral Ltd. Competitors by Market Cap
The table below lists competitors of Epigral Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Societe de la Tour Eiffel SA
PA:EIFF
|
$532.82 Million |
|
Wuxi Jinyang New Materials Co. Ltd. A
SHE:301210
|
$532.84 Million |
|
Neuropace Inc
NASDAQ:NPCE
|
$532.89 Million |
|
Solus Advanced Materials Co Ltd
KO:336370
|
$532.92 Million |
|
Beijing Hualian Department Store Co Ltd
SHE:000882
|
$532.75 Million |
|
Shanghai Yahong Moulding Co Ltd
SHG:603159
|
$532.65 Million |
|
Jiangsu United Water Technology Co. Ltd. Cl A
SHG:603291
|
$532.60 Million |
|
Invesco Quality Municipal Income Closed Fund
NYSE:IQI
|
$532.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Epigral Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 19,045,300,000 to 22,214,300,000, a change of 3,169,000,000 (16.6%).
- Net income of 3,319,700,000 contributed positively to equity growth.
- Dividend payments of 183,200,000 reduced retained earnings.
- Other comprehensive income increased equity by 2,466,800,000.
- Other factors decreased equity by 2,434,300,000.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs3.32 Billion | +14.94% |
| Dividends Paid | Rs183.20 Million | -0.82% |
| Other Comprehensive Income | Rs2.47 Billion | +11.1% |
| Other Changes | Rs-2.43 Billion | -10.96% |
| Total Change | Rs- | 16.64% |
Book Value vs Market Value Analysis
This analysis compares Epigral Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.22x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 36.69x to 2.22x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-03-31 | Rs31.12 | Rs1141.90 | x |
| 2016-03-31 | Rs41.71 | Rs1141.90 | x |
| 2017-03-31 | Rs51.12 | Rs1141.90 | x |
| 2018-03-31 | Rs124.51 | Rs1141.90 | x |
| 2019-03-31 | Rs118.60 | Rs1141.90 | x |
| 2020-03-31 | Rs100.48 | Rs1141.90 | x |
| 2021-03-31 | Rs117.09 | Rs1141.90 | x |
| 2022-03-31 | Rs174.72 | Rs1141.90 | x |
| 2023-03-31 | Rs257.30 | Rs1141.90 | x |
| 2024-03-31 | Rs301.83 | Rs1141.90 | x |
| 2025-03-31 | Rs450.88 | Rs1141.90 | x |
| 2026-03-31 | Rs514.92 | Rs1141.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Epigral Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.94%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 13.14%
- • Asset Turnover: 0.72x
- • Equity Multiplier: 1.58x
- Recent ROE (14.94%) is below the historical average (22.93%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 15.75% | 9.86% | 0.66x | 2.43x | Rs126.61 Million |
| 2016 | 22.76% | 16.87% | 0.74x | 1.83x | Rs376.67 Million |
| 2017 | 18.40% | 16.97% | 0.74x | 1.46x | Rs303.68 Million |
| 2018 | 30.05% | 26.04% | 0.89x | 1.30x | Rs1.04 Billion |
| 2019 | 37.10% | 25.74% | 0.68x | 2.12x | Rs1.34 Billion |
| 2020 | 19.20% | 18.36% | 0.48x | 2.18x | Rs536.51 Million |
| 2021 | 14.74% | 12.21% | 0.57x | 2.12x | Rs324.26 Million |
| 2022 | 34.82% | 16.31% | 0.73x | 2.93x | Rs1.80 Billion |
| 2023 | 33.05% | 16.28% | 0.89x | 2.28x | Rs2.46 Billion |
| 2024 | 15.62% | 10.34% | 0.68x | 2.23x | Rs704.56 Million |
| 2025 | 18.78% | 14.03% | 0.81x | 1.66x | Rs1.67 Billion |
| 2026 | 14.94% | 13.14% | 0.72x | 1.58x | Rs1.10 Billion |
Industry Comparison
This section compares Epigral Ltd.'s net assets metrics with peer companies in the Chemicals industry.
Industry Context
- Industry: Chemicals
- Average net assets among peers: $11,898,709,840
- Average return on equity (ROE) among peers: 19.23%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Epigral Ltd. (EPIGRAL) | Rs22.21 Billion | 15.75% | 0.58x | $532.76 Million |
| Archean Chemical Industries Limited (ACI) | $19.33 Billion | 5.53% | 0.38x | $700.22 Million |
| The Andhra Sugars Limited (ANDHRSUGAR) | $6.35 Billion | 17.21% | 1.15x | $123.89 Million |
| Bhansali Engineering Polymers Limited (BEPL) | $10.02 Billion | 17.96% | 0.10x | $288.13 Million |
| Chemplast Sanmar Limited (CHEMPLASTS) | $2.46 Billion | 7.18% | 2.72x | $384.86 Million |
| DCW Limited (DCW) | $3.75 Billion | 18.05% | 1.78x | $190.02 Million |
| Deepak Fertilizers and Petrochemicals Corporation Limited (DEEPAKFERT) | $62.54 Billion | 14.93% | 1.10x | $2.08 Billion |
| DIAMINES AND CHEMICALS ORD (BSE) (DIAMINESQ) | $210.14 Million | 44.52% | 1.62x | $26.51 Million |
| DMCC SPECIALITY CHEMICALS LIMITED (DMCC) | $1.98 Billion | 3.50% | 1.02x | $67.27 Million |
| Foseco India Limited (FOSECOIND) | $451.96 Million | 44.18% | 0.86x | $423.21 Million |
About Epigral Ltd.
Epigral Limited manufactures and sells chlor-alkali and derivative products in India and internationally. The company offers chlorinated polyvinyl chloride (CPVC) resin, epichlorohydrin, chloromethanes value chain, hydrogen peroxide, caustic soda and potash, chlorine, hydrogen, chloromethanes, captive power plant (CPP), and chlorotoluene value chain, as well as operates wind-solar hybrid power pl… Read more